Compass Therapeutics Inc. (CMPX) Stock Analysis

Compass Therapeutics Inc. (CMPX) is a publicly traded company in the HEALTHCARE sector. It trades at $2.08, carries a market capitalization of $428.61M. This page summarizes the public market data, fundamentals, and frequently asked questions for CMPX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Compass Therapeutics Inc. currently has a Bullish sentiment score of 0.21.

About Compass Therapeutics Inc.

Compass Therapeutics, Inc. is a Boston-based clinical-stage biopharmaceutical firm specializing in the development of innovative antibody-based therapies for cancer and other serious diseases. The company is focused on advancing its proprietary drug candidates through rigorous clinical trials, leveraging a state-of-the-art technology platform to create highly targeted treatments that aim to improve patient outcomes. With a pipeline dedicated to transforming the oncology landscape, Compass rep...

GNG Research Analysis

GNG Research scores Compass Therapeutics Inc. (CMPX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CMPX.

Frequently Asked Questions

Does CMPX pay dividends?

Compass Therapeutics Inc. (CMPX) does not currently pay a regular dividend.

What is CMPX's market cap?

Compass Therapeutics Inc. (CMPX) has a market capitalization of $428.61M with a current stock price of $2.08.